Results 61 to 70 of about 139,183 (310)

Animals Experimentally Infected with SARS-CoV-2 Generate Functional Autoantibodies against G-Protein-Coupled Receptors

open access: yesBiomedicines, 2023
(1) Background: SARS-CoV-2 infection has been linked to diverse clinical manifestations in humans, including cardiovascular complications. Functional autoantibodies targeting G-protein-coupled receptors have emerged as potential contributors to these ...
Gerd Wallukat   +4 more
doaj   +1 more source

Immunosuppressive Drugs in Early Systemic Sclerosis and Prevention of Damage Accrual

open access: yesArthritis Care &Research, EarlyView.
Objective Organ damage in patients with systemic sclerosis (SSc) in individual organs such as the lungs may be prevented by receiving immunosuppressive drugs (ISs). A new measure of global organ damage, the Scleroderma Clinical Trials Consortium Damage Index (SCTC‐DI), has allowed us to investigate whether receiving ISs may reduce global organ damage ...
Murray Baron   +29 more
wiley   +1 more source

Patients with ACPA-positive and ACPA-negative rheumatoid arthritis show different serological autoantibody repertoires and autoantibody associations with disease activity

open access: yesScientific Reports, 2023
Patients with rheumatoid arthritis (RA) can test either positive or negative for circulating anti-citrullinated protein antibodies (ACPA) and are thereby categorized as ACPA-positive (ACPA+) or ACPA-negative (ACPA−), respectively. In this study, we aimed
Kevin Y. Cunningham   +17 more
doaj   +1 more source

Sex‐Related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta‐Analysis

open access: yesArthritis Care &Research, EarlyView.
Objective We aimed to assess differences in baseline characteristics, efficacy, and safety of advanced therapies between male and female patients with axial spondyloarthritis (axSpA) in randomized controlled trials (RCTs). Methods We conducted a systematic literature search for RCTs assessing the efficacy of advanced therapies in patients with axSpA ...
Angel Gao   +5 more
wiley   +1 more source

Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches

open access: yesEuropean Journal of Immunology, Volume 53, Issue 1, January 2023., 2023
B lineage cells have been identified as therapeutic targets in autoimmune diseases. In the current review article, we provide an overview of novel strategies to target B lineage cells in autoimmune diseases, with a focus on inflammatory rheumatic diseases.
Ana Merino‐Vico   +3 more
wiley   +1 more source

Estimating AutoAntibody Signatures to Detect Autoimmune Disease Patient Subsets [PDF]

open access: yesarXiv, 2017
Autoimmune diseases are characterized by highly specific immune responses against molecules in self-tissues. Different autoimmune diseases are characterized by distinct immune responses, making autoantibodies useful for diagnosis and prediction. In many diseases, the targets of autoantibodies are incompletely defined.
arxiv  

Functional Polarization of Liver Macrophages by Glyco Gold Nanoparticles

open access: yesAdvanced Science, EarlyView.
Macrophages play a critical role in several pathophysiological diseases by being involved in the activation of adaptive and innate immune responses. The repolarization of macrophages using gold nanoparticles functionalized with glycans for a more selective targeting toward a restorative phenotype leads to an amelioration of the events.
Jennifer Fernandez Alarcon   +25 more
wiley   +1 more source

IL‐13 determines specific IgE responses and SARS‐CoV‐2 immunity after mild COVID‐19 and novel mRNA vaccination

open access: yesEuropean Journal of Immunology, Volume 52, Issue 12, Page 1972-1979, December 2022., 2022
To investigate atopic immune reactions in response to SARS‐CoV‐2 mRNA vaccinations or mild infections serum IgE and cytokines were analyzed. An atopic environment prone to reactions against aeroallergens was revealed in convalescents but not vaccinated.
Stefan Meltendorf   +13 more
wiley   +1 more source

YC‐4‐3, a Novel Glycogen Synthase Kinase 3β Inhibitor, Alleviates the Endoplasmic Reticulum Stress of Macrophages in Primary Immune Thrombocytopenia

open access: yesAdvanced Science, EarlyView.
A patented GSK‐3β inhibitor (GSK‐3βi), new benzothiazepinone compounds (BTZs), YC‐4‐3, can modulate the inflammatory status of macrophages in primary immune thrombocytopenia (ITP), and improve the thrombocytopenia in murine ITP models by directly interacting with endoplasmic reticulum (ER) stress response.
Pengcheng Xu   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy